WO2022265091A1 - ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物 - Google Patents

ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物 Download PDF

Info

Publication number
WO2022265091A1
WO2022265091A1 PCT/JP2022/024263 JP2022024263W WO2022265091A1 WO 2022265091 A1 WO2022265091 A1 WO 2022265091A1 JP 2022024263 W JP2022024263 W JP 2022024263W WO 2022265091 A1 WO2022265091 A1 WO 2022265091A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
peptide
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/024263
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
拓也 長谷崎
一登 山田
光広 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to EP22825079.1A priority Critical patent/EP4357354A1/en
Priority to US18/566,885 priority patent/US20240270801A1/en
Priority to JP2023530421A priority patent/JPWO2022265091A1/ja
Publication of WO2022265091A1 publication Critical patent/WO2022265091A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to epitope peptides of human ⁇ -synuclein and pharmaceutical compositions containing the peptides.
  • ⁇ -synuclein Human ⁇ -synuclein ( ⁇ Syn) is a protein encoded by the SNCA gene, consisting of 140 amino acids and having a molecular weight of 14.5 kDa. Highly expressed in the cerebellum. ⁇ -Synuclein is believed to be involved in synaptic activities such as the transport of synaptic vesicles, the control of neurotransmitter release, and the control of dopamine neurotransmission, but the full picture of its functions has not yet been elucidated. . On the other hand, ⁇ -synuclein is also known as a major constituent protein of Lewy bodies, which are pathological structures characteristic of the brains of patients with various neurodegenerative diseases. A Lewy body is an abnormal circular structure (inclusion body) found inside a nerve cell.
  • Synucleinopathies are neurodegenerative diseases characterized by the accumulation of abnormal aggregates of the alpha-synuclein protein in neurons, nerve fibers or glial cells, primarily Parkinson's disease (PD ), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and the like (Non-Patent Document 1).
  • PD Parkinson's disease
  • DLB dementia with Lewy bodies
  • MSA multiple system atrophy
  • Non-Patent Document 2 discloses that pathological ⁇ -synuclein propagates from the olfactory bulb and vagus nerve to the cerebral cortex as the disease progresses.
  • Patent Document 1 describes a pharmaceutical composition comprising alpha-synuclein, an immunogenic fragment of alpha-synuclein, an antibody against alpha-synuclein, or an antibody against an immunogenic fragment of alpha-synuclein for the prevention or treatment of Lewy body disease.
  • the immunogenic fragment comprises amino acids 130-140 of alpha-synuclein and has less than 40 amino acids.
  • epitope peptides or mimotope peptides of ⁇ -synuclein that induce antibodies against ⁇ -synuclein have also been reported (Patent Documents 2 and 3).
  • a conjugate vaccine is provided by linking a carrier protein to an antigen to provide a vaccine with a higher ability to induce antibodies.
  • Carrier proteins that can be used in conjugate vaccines preferably have immunostimulatory properties and low antigenicity, such as the OSK-1 peptide and KLH described in Patent Document 4, for example.
  • Non-Patent Document 4 It is thought that the antibody that binds to the monomer is captured in the periphery and does not migrate to the brain. Therefore, when trying to use an antibody against ⁇ -synuclein as a therapeutic agent, it would be more desirable to use an antibody that has the ability to bind to oligomers.
  • An object of the present invention is to provide epitope peptides of human ⁇ -synuclein and pharmaceutical compositions containing the peptides, which have a high ability to induce antibodies against not only ⁇ -synuclein monomers but also ⁇ -synuclein oligomers.
  • the present inventors have found that administration of a polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 1 or SEQ ID NO: 2 and a mimetic thereof (mimotope) to mice induces anti- ⁇ -synuclein monomer antibody and anti-synuclein oligomer antibody. It was found that it was done, and it led to the completion of the present invention.
  • a polypeptide consisting of any of the following amino acid sequences: (a) the amino acid sequence shown in SEQ ID NO: 1, (b) the amino acid sequence represented by SEQ ID NO: 2, and (c) substitution, deletion, addition and/or insertion of 1, 2 or 3 amino acids in the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 amino acid sequence.
  • the polypeptide of [1] wherein the amino acid sequence is the amino acid sequence shown in SEQ ID NO:1.
  • the polypeptide of [1], wherein the amino acid sequence is the amino acid sequence shown in SEQ ID NO:2.
  • [12] The conjugate according to any one of [8] to [11], wherein the C-terminal amino acid of the conjugate is amidated.
  • a pharmaceutical composition comprising the polypeptide of any one of [1] to [5] or the conjugate of any one of [6] to [12].
  • the pharmaceutical composition of [15] wherein the neurodegenerative disease is a disease associated with ⁇ -synuclein accumulation.
  • the pharmaceutical composition of [16], wherein the disease associated with ⁇ -synuclein accumulation is Parkinson's disease.
  • [18] A nucleic acid encoding the polypeptide of any one of [1] to [5], or the conjugate of [8] or [10].
  • [19] An expression vector comprising the nucleic acid of [18].
  • [20] A recombinant cell obtained by transforming a host cell with the expression vector of [19].
  • [21] An antibody that specifically binds to the polypeptide according to any one of [1] to [5].
  • [22] A pharmaceutical composition comprising the nucleic acid of [18], the expression vector of [19], or the antibody of [21].
  • the pharmaceutical composition of [19] for prevention, amelioration, or treatment of neurodegenerative diseases.
  • polypeptide according to any one of [1] to [5] or the conjugate according to any one of [6] to [12] in the production of vaccines for the prevention, improvement, or treatment of neurodegenerative diseases use.
  • the polypeptide of the present invention can induce neutralizing antibodies against not only ⁇ -synuclein monomers but also ⁇ -synuclein oligomers. Therefore, therapeutic effects on neurodegenerative diseases such as Parkinson's disease can be expected.
  • FIG. 2 shows the results of evaluating Syn phosphorylation by aggregated Syn in SH-SY5Y cells in Example 5.
  • FIG. 5 shows the results of evaluating the human ⁇ Syn-neutralizing activity of the antibody induced in mice by the AJ-human ⁇ Syn peptide conjugate in Example 5.
  • FIG. 10 shows the results of dot blot evaluation of the inhibitory effect of AJ-human ⁇ Syn peptide conjugate on human ⁇ Syn propagation to the cortex in human ⁇ Syn overexpressing mice in Example 6.
  • FIG. 10 shows the results of dot blot evaluation of the inhibitory effect of AJ-human ⁇ Syn peptide conjugate on human ⁇ Syn propagation to the olfactory bulb in human ⁇ Syn overexpressing mice in Example 6.
  • FIG. 6 shows the results of Western blot evaluation of the inhibitory effect of AJ-human ⁇ Syn peptide conjugate on human ⁇ Syn propagation to the cortex in human ⁇ Syn overexpressing mice in Example 6.
  • FIG. 6 shows the results of Western blot evaluation of the inhibitory effect of the AJ-human ⁇ Syn peptide conjugate on human ⁇ Syn propagation to the olfactory bulb in human ⁇ Syn overexpressing mice in Example 6.
  • FIG. 6 shows the results of dot blot evaluation of the inhibitory effect of AJ-human ⁇ Syn peptide conjugate on human ⁇ Syn propagation to the olfactory bulb in human ⁇ Syn overexpressing mice in Example 6.
  • FIG. 2 shows the results of evaluating the ability of AJ-human ⁇ Syn peptide conjugates to induce anti- ⁇ Syn monomer antibodies in cynomolgus monkeys in Example 7.
  • FIG. 2 shows the results of evaluating the ability of AJ-human ⁇ Syn peptide conjugates to induce anti- ⁇ Syn oligomer antibodies in cynomolgus monkeys in Example 7.
  • FIG. 10 shows the results of evaluating the human ⁇ Syn-neutralizing activity of antibodies induced in cynomolgus monkeys by the AJ-human ⁇ Syn peptide conjugate in Example 8.
  • FIG. 1 shows the results of evaluating the ability of AJ-human ⁇ Syn peptide conjugates to induce anti- ⁇ Syn monomer antibodies in cynomolgus monkeys in Example 7.
  • FIG. 10 shows the results of evaluating the human ⁇ Syn-neutralizing activity of antibodies induced in cynomolgus monkeys
  • ⁇ -synuclein Human ⁇ -synuclein ( ⁇ Syn) is encoded by the SNCA gene (Genbank No: 6622, Gene Accession No: NP — 000336.1, Protein Accession No: P37840), consists of 140 amino acids shown in SEQ ID NO: 14, and has a molecular weight of 14.5 kDa. is protein. Abnormally aggregated aggregates (oligomers) of highly phosphorylated ⁇ Syn are major constituents of Lewy bodies, and synucleinopathy is a neurodegenerative disease characterized by the accumulation of abnormal aggregates of ⁇ Syn. It is also known that As opposed to aggregates (oligomers), non-aggregated ⁇ Syn is called a monomer of ⁇ Syn.
  • a polypeptide of one embodiment consists of any of the following amino acid sequences: (a) the amino acid sequence shown in SEQ ID NO: 1, (b) the amino acid sequence represented by SEQ ID NO: 2, and (c) substitution, deletion, addition and/or insertion of 1, 2 or 3 amino acids in the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 amino acid sequence.
  • the polypeptide consisting of the amino acid sequence (KKDQLGKNE) shown in SEQ ID NO: 1 is a polypeptide consisting of the 96th to 104th amino acids (aa) of human ⁇ Syn shown in SEQ ID NO: 14, and is referred to herein as p54.
  • a polypeptide consisting of the amino acid sequence (EAYEMPSEE) shown in SEQ ID NO: 2 is a polypeptide consisting of amino acids 123-131 of human ⁇ Syn shown in SEQ ID NO: 14, and is referred to herein as p150.
  • p54 and p150 are excellent neutralizing antibody-inducing epitopes and can induce neutralizing antibodies against not only ⁇ -synuclein monomers, but also ⁇ -synuclein oligomers. Therefore, p54 and p150 can be vaccines for the prevention, amelioration, or treatment of diseases associated with ⁇ -synuclein accumulation.
  • mimotopes In addition to the two epitopes (antigenic determinants) of p54 and p150, polypeptides (mimetics) that mimic the structures of these epitopes (mimetics), so-called “mimotopes”, can also be useful antigens.
  • a mimetic may be a polypeptide consisting of the amino acid sequence shown in (c) above.
  • substitution, deletion, addition and/or insertion of 1, 2 or 3 amino acids means that 1, 2 at any position in the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or substitution, deletion, addition and/or insertion of three amino acids, or substitution, deletion, addition and/or insertion of any amino acid.
  • Amino acids to be substituted, inserted or added may be natural or non-natural.
  • Natural amino acids include L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L -methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like.
  • non-natural amino acids include D-form amino acids of the above-described natural amino acids and derivatives of natural amino acids obtained by introducing various substituents into the natural amino acids.
  • Substitution of amino acids is not particularly limited, and for example, examples of mutually substitutable amino acids having similar chemical properties are shown below. Amino acids contained in the same group can be substituted with each other (so-called conservative substitution), but amino acids at positions that have little effect on epitope properties may be substituted with amino acids contained in different groups. .
  • Group 1 leucine (L), isoleucine (I), norleucine, valine (V), norvaline, alanine (A), 2-aminobutanoic acid, methionine (M), o-methylserine, t-butylglycine, t-butylalanine , cyclohexylalanine group 2: aspartic acid (D), glutamic acid (E), isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid group 3: asparagine (N), glutamine (Q) Group 4: Lysine (K), Arginine (R), Ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid Group 5: Proline (P), 3-hydroxyproline, 4-hydroxyproline Group 6: serine (S), threonine (T), homoserine group 7: phenylalanine (F), tyros
  • 1, 2 or 3 amino acid substitutions or insertions in the amino acid sequence shown in SEQ ID NO: 1 include any There may be 1, 2 or 3 amino acid substitutions or insertions at positions, for example 1, 2 or 3 at any position at positions 97, 98, 99, 102, 103, 104 There may be a single amino acid substitution.
  • Deletion of 1, 2 or 3 amino acids in the amino acid sequence shown by SEQ ID NO: 1 is any position at positions 96, 97, 98, 99, 100, 101, 102, 103 and 104 of SEQ ID NO: 14 may be a 1, 2 or 3 amino acid deletion of
  • the addition of 1, 2 or 3 amino acids in the amino acid sequence shown in SEQ ID NO: 1 includes addition of 1, 2 or 3 at the N-terminus or C-terminus of the polypeptide of the amino acid sequence shown in SEQ ID NO: 1.
  • It may be an amino acid addition, for example, amino acid 95 of SEQ ID NO: 14, two amino acids 94-95, or three One amino acid may be added, and the 105th amino acid of SEQ ID NO: 14 to the C-terminus of the polypeptide of the amino acid sequence shown in SEQ ID NO: 14, two amino acids of 105th to 106th or three of 105th to 107th An amino acid may be added, and may be added to both the N-terminus and the C-terminus of the polypeptide having the amino acid sequence shown in SEQ ID NO: 1.
  • the 95th amino acid of SEQ ID NO: 14 may be added to the N-terminus.
  • the 105th and 106th amino acids may be added to the C-terminus, and the 94th and 95th amino acids of SEQ ID NO: 14 are added to the N-terminus, and the 105th amino acid is added to the C-terminus. Further, the 95th amino acid of SEQ ID NO: 14 may be added to the N-terminus and the 105th amino acid to the C-terminus. Any combination of substitutions, deletions, additions or insertions may be made.
  • 1, 2 or 3 amino acid substitutions or insertions in the amino acid sequence shown by SEQ ID NO: 2 include any 1, 2 or 3 amino acid substitutions or insertions at any position, e.g. 1, 2 or 3 amino acid substitutions at any position at positions 123, 125, 131 of SEQ ID NO: 14 to any amino acid.
  • the deletion of 1, 2 or 3 amino acids in the amino acid sequence shown by SEQ ID NO: 2 is any position at positions 123, 124, 125, 126, 127, 128, 129, 130 and 131 of SEQ ID NO: 14 may be a 1, 2 or 3 amino acid deletion of
  • the addition of 1, 2 or 3 amino acids in the amino acid sequence shown by SEQ ID NO: 2 includes 1, 2 or 3 at the N-terminus or C-terminus of the polypeptide of the amino acid sequence shown by SEQ ID NO: 2.
  • amino acid 122 of SEQ ID NO: 14 two amino acids 121-122, or amino acids 120-122 at the N-terminus of the polypeptide of the amino acid sequence shown in SEQ ID NO: 2 3 amino acids may be added, and the 132nd amino acid of SEQ ID NO: 14 to the C-terminus of the polypeptide of the amino acid sequence shown in SEQ ID NO: 2, the two amino acids 132-133, or 132-134th 3 amino acids may be added, and amino acids may be added to both the N-terminus and the C-terminus of the polypeptide of the amino acid sequence shown in SEQ ID NO: 2, for example, 122nd of SEQ ID NO: 14 may be added to the N-terminus, the 132nd and 133rd amino acids may be added to the C-terminus, and the 121st and 122nd amino acids of SEQ ID NO: 14 are added to the N-terminus, and the 132nd An amino acid may be added to the C-terminus, and the
  • polypeptide consisting of the amino acid sequence shown in (c) above include substitution, deletion, addition and/or insertion of 1, 2 or 3 amino acids in the amino acid sequence shown in SEQ ID NO: 1.
  • SEQ ID NO: 3 SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 18-21, which is an amino acid sequence in which 1, 2 or 3 amino acids are substituted, deleted, added and/or inserted and a polypeptide consisting of an amino acid sequence represented by That is, p283, p142, p167, p227, p233, p272, p273, p276, p277, p242, p244, p347, p361, p229, p237, and p298 below.
  • p167, p227, p272, p276, p283, p242, p244, and p229 are particularly preferred because of their high ability to induce neutralizing antibodies against ⁇ -synuclein oligomers.
  • p283 (123-132aa of SEQ ID NO: 14, E131D): EAYEMPSEDG (SEQ ID NO: 3).
  • "123-132aa, E131D of SEQ ID NO: 14” means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 131st glutamic acid (E) is substituted with aspartic acid (D).
  • the amino acid sequence of p283 is obtained by substituting glutamic acid (E) at position 9 of the amino acid sequence shown by SEQ ID NO: 2 with aspartic acid (D), and adding SEQ ID NO: 132nd glycine (G) of the amino acid sequence shown by 14 was added as the 10th amino acid.
  • p142 (96-104aa of SEQ ID NO: 14, K102A): KKDQLGANE (SEQ ID NO: 4).
  • "96-104aa of SEQ ID NO: 14, K102A” means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 102nd lysine (K) is substituted with alanine (A) means that there is The amino acid sequence of p142 is obtained by substituting alanine (A) for 7th lysine (K) in the amino acid sequence shown in SEQ ID NO:1.
  • p167 (96-105aa of SEQ ID NO: 14): KKDQLGKNEE (SEQ ID NO: 5).
  • “96-105aa of SEQ ID NO:14” means corresponding to the 96th-105th sequence of the amino acid sequence shown in SEQ ID NO:14.
  • the amino acid sequence of p167 is obtained by adding the 105th glutamic acid (E) of the amino acid sequence shown by SEQ ID NO: 14 as the 10th amino acid to the C-terminal of the amino acid sequence shown by SEQ ID NO: 1.
  • p227 (96-104aa of SEQ ID NO: 14, K97R): KRDQLGKNE (SEQ ID NO: 6).
  • "96-104aa, K97R of SEQ ID NO: 14” means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 97th lysine (K) is substituted with arginine (R).
  • arginine (R) means that there is The amino acid sequence of p227 is obtained by substituting arginine (R) for the second lysine (K) in the amino acid sequence shown in SEQ ID NO:1.
  • telomere sequence of SEQ ID NO: 14 means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 104th glutamic acid (E) is substituted with aspartic acid (D).
  • the amino acid sequence of p227 is obtained by substituting glutamic acid (E) at position 9 of the amino acid sequence shown in SEQ ID NO: 1 with aspartic acid (D).
  • 96-104aa of SEQ ID NO: 14, D98N, E104D KKNQLGKND (SEQ ID NO: 8).
  • 96-104aa, D98N, E104D of SEQ ID NO: 14 means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 98th aspartic acid (D) is asparagine (N). and that glutamic acid (E) at position 104 is substituted with aspartic acid (D).
  • amino acid sequence of p272 is obtained by substituting asparagine (N) for aspartic acid (D) at position 3 and glutamic acid (E) at position 9 of the amino acid sequence shown in SEQ ID NO: 1 for aspartic acid (D). It is a thing.
  • 96-104aa of SEQ ID NO: 14, D98T, E104D KKTQLGKND (SEQ ID NO: 9).
  • 96-104aa, D98T, E104D of SEQ ID NO: 14 means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 98th aspartic acid (D) is threonine (T) and that glutamic acid (E) at position 104 is substituted with aspartic acid (D).
  • the amino acid sequence of p273 is obtained by substituting threonine (T) for aspartic acid (D) at position 3 and glutamic acid (E) at position 9 in the amino acid sequence shown in SEQ ID NO: 1 for aspartic acid (D). It is a thing.
  • p276 (123-132aa of SEQ ID NO: 14, E123D): DAYEMPSEEG (SEQ ID NO: 10).
  • "123-132aa, E123D of SEQ ID NO: 14” means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 123rd glutamic acid (E) is substituted with aspartic acid (D).
  • the amino acid sequence of p276 is obtained by replacing the first glutamic acid (E) in the amino acid sequence shown by SEQ ID NO: 2 with aspartic acid (D), and adding SEQ ID NO: 132nd glycine (G) of the amino acid sequence shown by 14 was added as the 10th amino acid.
  • p277 (123-132aa of SEQ ID NO: 14, Y125F): EAFEMPSEEG (SEQ ID NO: 11).
  • "123-132aa, Y125F of SEQ ID NO: 14” means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 125th tyrosine (Y) is substituted with phenylalanine (F).
  • the amino acid sequence of p277 is obtained by replacing the third tyrosine (Y) in the amino acid sequence shown by SEQ ID NO: 2 with phenylalanine (F), and adding SEQ ID NO: 14 to the C-terminus of the amino acid sequence shown by SEQ ID NO: 2.
  • the 132nd glycine (G) of the amino acid sequence shown in is added as the 10th amino acid.
  • p242 (123-132aa of SEQ ID NO: 14, E123A): AAYEMPSEEG (SEQ ID NO: 18).
  • “123-132aa, E123A of SEQ ID NO: 14” means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 123rd glutamic acid (E) is substituted with alanine (A) means that there is
  • the amino acid sequence of p242 is such that the first glutamic acid (E) in the amino acid sequence shown in SEQ ID NO: 2 is replaced with alanine (A), and the C-terminal of the amino acid sequence shown in SEQ ID NO: 2 is replaced with SEQ ID NO: 14.
  • the 132nd glycine (G) of the amino acid sequence shown was added as the 10th amino acid.
  • p244 (123-132aa of SEQ ID NO: 14, Y125A): EAAEMPSEEG (SEQ ID NO: 19).
  • "123-132aa, Y125A of SEQ ID NO: 14” means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 125th tyrosine (Y) is substituted with alanine (A) means that there is
  • the amino acid sequence of p244 is such that the third tyrosine (Y) in the amino acid sequence shown in SEQ ID NO: 2 is replaced with alanine (A), and the C-terminal of the amino acid sequence shown in SEQ ID NO: 2 is replaced with SEQ ID NO: 14.
  • the 132nd glycine (G) of the amino acid sequence shown was added as the 10th amino acid.
  • p347 (123-132aa, E123H, Y125F of SEQ ID NO: 14): HAFEMPSEEG (SEQ ID NO: 20).
  • 123-132aa, E123H, Y125F of SEQ ID NO: 14 means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 123rd glutamic acid (E) is substituted with histidine (H). and tyrosine (Y) at position 125 is substituted with phenylalanine (F).
  • the first glutamic acid (E) in the amino acid sequence shown in SEQ ID NO: 2 is substituted with histidine (H)
  • the third tyrosine (Y) is substituted with phenylalanine (F)
  • the sequence The 132nd glycine (G) of the amino acid sequence shown by SEQ ID NO: 14 was added as the 10th amino acid to the C-terminus of the amino acid sequence shown by No. 2.
  • p361 (123-132aa, E123D, Y125F of SEQ ID NO: 14): DAFEMPSEEG (SEQ ID NO: 21).
  • 123-132aa, E123D, Y125F of SEQ ID NO: 14 means that in the 123-132nd sequence of the amino acid sequence shown in SEQ ID NO: 14, the 123rd glutamic acid (E) is replaced by aspartic acid (D). and that tyrosine (Y) at position 125 is substituted with phenylalanine (F).
  • the first glutamic acid (E) of the amino acid sequence shown in SEQ ID NO: 2 is substituted with aspartic acid (D)
  • the third tyrosine (Y) is substituted with phenylalanine (F)
  • the 132nd glycine (G) of the amino acid sequence shown by SEQ ID NO: 14 was added as the 10th amino acid to the C-terminus of the amino acid sequence shown by SEQ ID NO: 2.
  • p229 (96-104aa of SEQ ID NO: 14, D98T): KKTQLGKNE (SEQ ID NO: 22).
  • "96-104aa of SEQ ID NO: 14, D98T” means that in the 96th-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 98th aspartic acid (D) is substituted with threonine (T).
  • T threonine
  • the amino acid sequence of p229 is obtained by substituting threonine (T) for the third aspartic acid (D) in the amino acid sequence shown in SEQ ID NO:1.
  • telomere sequence shown in SEQ ID NO: 14 means that in the 96-104th sequence of the amino acid sequence shown in SEQ ID NO: 14, the 98th aspartic acid (D) is substituted with asparagine (N).
  • the amino acid sequence of p237 is obtained by substituting asparagine (N) for the third aspartic acid (D) in the amino acid sequence shown in SEQ ID NO:1.
  • 96-104aa, Q99E, N103D of SEQ ID NO: 14 KKDELGKDE (SEQ ID NO: 24).
  • 96-104aa, Q99E, N103D of SEQ ID NO: 14 means that in the 96th-104th sequences of the amino acid sequence shown in SEQ ID NO: 14, the 99th glutamine (Q) is substituted with glutamic acid (E). and the 103rd asparagine (N) is substituted with aspartic acid (D).
  • amino acid sequence of p298 is obtained by substituting glutamine (Q) at position 4 with glutamic acid (E) and asparagine (N) at position 8 with aspartic acid (D) in the amino acid sequence shown in SEQ ID NO: 1. is.
  • the polypeptide of this embodiment can be produced by genetic engineering techniques.
  • the production method is not particularly limited.
  • a nucleic acid encoding a desired polypeptide is obtained by PCR, the nucleic acid is operatively linked to an expression promoter, and optionally a nucleic acid encoding a carrier protein and a nucleic acid encoding a tag are also linked, and an appropriate expression vector is prepared.
  • the cDNA of the SNCA gene is used as a template, mutation is introduced by a site-directed mutagenesis method, and a base sequence encoding another amino acid residue is substituted to encode a polypeptide that is a mimotope.
  • Nucleic acids can be obtained. Furthermore, it can also be produced by designing and artificially synthesizing a nucleic acid encoding a desired amino acid sequence without using a template.
  • the nucleic acid may be DNA or RNA.
  • the polypeptide of the present embodiment is a short peptide, it can be produced by artificial synthesis according to the desired amino acid sequence.
  • the method of artificial synthesis is not particularly limited as long as it is a known method, and examples thereof include solid-phase synthesis methods such as the Fmoc method and Boc method, and liquid-phase synthesis methods.
  • the produced polypeptide may be purified as necessary.
  • the purification method is not particularly limited, but purification using an affinity chromatography column or the like can be mentioned.
  • a conjugate of one embodiment comprises a polypeptide of the above embodiments and a carrier protein.
  • the polypeptide and carrier protein are chemically linked.
  • the carrier protein is not particularly limited as long as it can increase the antigenicity of the antigenic peptide.
  • carrier proteins a peptide (herein referred to as "AJ peptide") consisting of an amino acid sequence identical or substantially identical to the amino acid sequence shown in SEQ ID NO: 13 (ELKLIFLHRLKRLRKRLKRK) is also preferably used. Since the AJ peptide itself has low antigenicity, it is possible to reduce unfavorable effects resulting from the antigenicity of the carrier protein. In addition, although the AJ peptide is short, it has a strong adjuvant effect (Patent Document 4).
  • the amino acid sequence substantially identical to the amino acid sequence shown in SEQ ID NO: 13 means that 1 to 4 amino acids are substituted, deleted, added and/or inserted in the amino acid sequence shown in SEQ ID NO: 13.
  • 1 to 3 more preferably 1 to 2, and even more preferably 1 amino acid is substituted, deleted, added and/or inserted.
  • the substantially identical amino acid sequence refers to an amino acid sequence having 80% or more homology with the amino acid sequence shown in SEQ ID NO: 13, preferably 85% or more, more preferably 90% or more, still more preferably 95% It is an amino acid sequence having the above homology.
  • a peptide consisting of an amino acid sequence substantially identical to the amino acid sequence shown by SEQ ID NO: 13 is preferably a peptide having substantially the same activity as the peptide consisting of the amino acid sequence shown by SEQ ID NO: 13.
  • the antibody-inducing ability of a conjugate of a peptide consisting of an amino acid sequence substantially identical to the peptide consisting of the amino acid sequence shown by SEQ ID NO: 13 and an epitope and the peptide consisting of the amino acid sequence shown by SEQ ID NO: 13 It is preferably equal to or greater than the ability to induce antibodies by the conjugate of the epitope.
  • a conjugate obtained by similarly linking a peptide consisting of the amino acid sequence shown in SEQ ID NO: 13 (reference peptide) or a peptide to be evaluated to the same antigen epitope Animals can be immunized in the same manner using gates, and the antibody titers of the obtained immune sera can be measured and compared by ELISA for evaluation.
  • the peptide to be evaluated is 80% or more, preferably 90% or more, more preferably 95% or more of the antibody titer of the conjugate linked to the reference peptide
  • the peptide to be evaluated is It can be evaluated as having an antibody-inducing ability equal to or greater than that of the reference peptide.
  • the antibody titer can be measured by a conventional method, such as the method described in Examples.
  • the polypeptide and carrier protein may be linked in the order of polypeptide and carrier protein from the N-terminal side, or may be linked in the order of carrier protein and polypeptide. Furthermore, one type of carrier protein may be used, or two types may be used. In the case of two types, the carrier protein of the first type, the polypeptide, and the carrier protein of the second type may be linked in this order from the N-terminal side.
  • the N-terminal amino acid of the conjugate is preferably acetylated, and the C-terminal amino acid is amidated. preferably.
  • the polypeptide and carrier protein may be fused via a peptide linker or directly, or may be chemically linked via a linker, or both the linker and the peptide linker in a chemical linkage. may be connected via
  • the peptide linker is not particularly limited. Peptide linkers consisting of naturally occurring L-amino acids or repeating sequences thereof can be mentioned.
  • amino acids may be natural L-amino acids or D-amino acids.
  • the linker for chemical ligation is not particularly limited, and examples thereof include ⁇ -aminocaproic acid, ⁇ -aminoalanine, ⁇ -aminobutyric acid, 7-aminoheptanoic acid, 12-aminolauric acid, glutamic acid, p-aminobenzoic acid, and the like. mentioned.
  • the AJ peptide and the polypeptide may be linked via ⁇ -aminocaproic acid, and KLH and the polypeptide may be linked via a peptide linker such as cysteine.
  • the AJ peptide and the above polypeptide may be linked via ⁇ -aminocaproic acid and/or a peptide linker.
  • conjugates include AJ-p54, AJ-p150, AJ-p283, AJ-p54-KLH, KLH-AJ-p54, KLH-p54, p54-KLH, AJ-p142, AJ- p167, AJ-p227, AJ-p233, AJ-p272, AJ-p273, AJ-p276, AJ-p277, AJ-p242, AJ-p244, AJ-p347, AJ-p361, AJ-p229 shown in Table 5, AJ-p237, AJ-p298.
  • AJ-p54, AJ-p150, AJ-p167, AJ-p227, AJ-p272, AJ-p276, AJ-p283, AJ-p242, AJ-p244, and AJ-p229 in particular neutralize ⁇ -synuclein oligomers. It has a high ability to induce antibodies and is preferably used.
  • the conjugate can be made by methods known to those skilled in the art.
  • the conjugate is a fusion protein
  • a nucleic acid encoding the fusion protein in which the polypeptide and carrier protein are operatively linked, optionally via a peptide linker, is prepared by PCR as described above
  • a conjugate, which is a fusion protein can be obtained by functionally linking a nucleic acid with an expression promoter, introducing it into an appropriate expression vector, and expressing it in a host cell.
  • the fusion protein has a short amino acid sequence, it can also be produced by artificial synthesis using a known peptide synthesis method (eg, solid-phase synthesis method).
  • a conjugate linked via a chemical linker can be prepared by preparing the peptide and carrier protein separately and then connecting them. For example, obtain by preparing a polypeptide that is an epitope and a carrier protein, adding a protecting group, linking via a chemical linker (eg, ⁇ -aminocaproic acid), and performing condensation and deprotection. can be done.
  • protecting groups include tBOC (tert-Butyl Oxy Carbonyl) group, FMOC (Fluorenyl-MethOxy-Carbonyl) group and the like.
  • condensing agents include carbodiimide compounds such as DCC (N,N'-Dicyclohexylcarbodiimide), EDC ((N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide), and imidazoles such as CDI (1,1'-Carbonyldiimidazole).
  • phosphonium salt compounds such as BOP (benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate), HBTU (O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyloxifluorophosphate)
  • Uronium salt compounds such as (O-(6-Chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) can be used.
  • ⁇ antibody ⁇ One embodiment provides antibodies that specifically bind to polypeptides that are epitopes (including mimotopes) of human alpha-synuclein ( ⁇ Syn). The antibody of this embodiment is used for prevention, amelioration, or treatment of neurodegenerative diseases.
  • the neurodegenerative disease may be a disease associated with ⁇ -synuclein accumulation.
  • Accumulation of ⁇ -synuclein means accumulation of ⁇ -synuclein aggregates (also referred to as “aggregated ⁇ -synuclein” or “ ⁇ -synuclein oligomers”) in nerve cells, nerve fibers or glial cells.
  • Associated diseases include Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), neurodegeneration with brain iron accumulation (NBIA) and other synucleinopathies, particularly Parkinson's disease. Therefore, the antibody of the present embodiment is preferably capable of specifically binding not only to ⁇ Syn monomers but also to aggregated ⁇ -synuclein.
  • Antibodies can be obtained from immune sera by immunizing mammals with the above polypeptides or conjugates or the following pharmaceutical compositions (vaccine) by known methods.
  • the dose and administration interval may be as described in [Pharmaceutical composition] below.
  • Mammals include mammals such as humans, Chinese hamsters, mice, rats, rabbits, dogs, pigs, monkeys, goats and horses. Therefore, the antibodies may be antibodies derived from these mammals, preferably human antibodies (humanized antibodies). Moreover, it may be a chimeric antibody or a humanized antibody.
  • a chimeric antibody can, for example, comprise a variable region from one animal species and a constant region from another animal species.
  • a chimeric antibody can be an antibody (humanized antibody) having a variable region derived from a mouse monoclonal antibody and a constant region derived from a human antibody.
  • the antibody may be a monoclonal antibody or a polyclonal antibody, preferably a monoclonal antibody. Moreover, the antibody may be a full-length antibody (natural antibody) or an antigen-binding fragment.
  • Native antibodies can be selected from the group consisting of IgG, IgM, IgA, IgD and IgE.
  • Antigen-binding fragments include (i) a Fab fragment, which is a monovalent fragment consisting of the V L , V H , C L , and C H1 domains; (ii) two Fab fragments linked by a disulfide bridge at the hinge region.
  • the antibody of this embodiment is administered in an effective amount for prevention, amelioration, or treatment of neurodegenerative diseases.
  • the administration subject may be a mammal such as a human, and is particularly preferably a human. Dosage amounts and intervals vary depending on the half-life of the antibody in the subject.
  • the dose may be, for example, 0.0001 mg/kg to 100 mg/kg body weight, such as 0.01 mg/kg to 10 mg/kg body weight, or 0.1 to 10 mg/kg.
  • the administration interval is not particularly limited, and may be once every two weeks, once a month, once every 3 to 6 months, once a year, or once every 2 to 5 years.
  • Dosing intervals are irregular, such as monitoring the concentration of anti-alpha-synuclein antibody in the subject's plasma and administering when it falls below a certain threshold (eg, 1-1000 ⁇ g/ml plasma antibody concentration). Dosing intervals may also be used. Alternatively, one type of antibody may be used, or two or more types of monoclonal antibodies with different binding specificities may be administered simultaneously or alternately.
  • the administration route is not particularly limited, and oral, parenteral, topical, intravenous, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, intranasal, and intramuscular routes can be mentioned.
  • nucleic acids, expression vectors, recombinant cells One embodiment provides a nucleic acid encoding a conjugate that is a polypeptide or fusion protein as described above.
  • the nucleic acid of this embodiment is used for prevention, amelioration, or treatment of neurodegenerative diseases.
  • the neurodegenerative disease is as described above.
  • the nucleic acid of the present embodiment is a nucleic acid that encodes the conjugate, which is the above-described polypeptide or fusion protein, and may be DNA or RNA. Nucleic acids may be prepared by PCR as described above, or may be artificially synthesized.
  • An expression vector of one embodiment comprises a nucleic acid encoding the conjugate that is the above-described polypeptide or fusion protein.
  • the expression vector is not particularly limited as long as it is a vector capable of autonomous replication in a host cell and/or a vector capable of integration into the chromosome of the host cell and capable of transcribing and expressing the above nucleic acid.
  • the expression vector preferably further contains a promoter, a ribosome binding sequence, and a transcription termination sequence in addition to the above nucleic acids, and further contains a gene that controls the promoter.
  • Such vectors may be known vectors, and a suitable vector can be selected by a person skilled in the art depending on the host cell.
  • expression vectors include retroviral systems, adenoviral vectors, adeno-associated viral vectors, viral vectors derived from Poxviridae including vaccinia virus and avian poxvirus, viral vectors derived from the genus Alphavirus, Venezuelan equine encephalitis virus, rhabdovirus, and the like. can be used.
  • a nucleic acid encoding a conjugate that is a polypeptide or a fusion protein, or an expression vector containing the nucleic acid can be encapsulated in liposomes.
  • a nucleic acid encoding a conjugate, which is a polypeptide or fusion protein, or an expression vector containing the nucleic acid can also be adsorbed to or associated with a particulate carrier (eg, polymethylmethacrylate polymer).
  • An effective amount of a nucleic acid encoding a conjugate that is a polypeptide or a fusion protein, an expression vector containing the nucleic acid, a liposome encapsulating the nucleic acid or the expression vector, or an effective amount for the prevention, amelioration, or treatment of a neurodegenerative disease , a particulate carrier carrying the nucleic acid or expression vector may be administered to the subject.
  • the administration route is not particularly limited, and oral, parenteral, topical, intravenous, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, intranasal, and intramuscular routes can be mentioned.
  • the dose may be, for example, 0.0001 mg to 100 mg, such as 0.001 mg to 10 mg, in terms of the amount of nucleic acid encoding the conjugate, which is a polypeptide or fusion protein.
  • the administration interval is not particularly limited, and may be once every two weeks, once a month, once every 3 to 6 months, once a year, or once every 2 to 5 years.
  • Expression of the nucleic acid produces the epitope in the body and induces antibodies that specifically bind to the epitope in the subject. Therefore, the dosing interval is such that the concentration of anti- ⁇ -synuclein antibody in the plasma of the subject is monitored and administered when it falls below a certain threshold (eg, plasma antibody concentration of 1-1000 ⁇ g/ml). Regular dosing intervals may also be used.
  • a recombinant cell of one embodiment is a recombinant cell obtained by transforming a host cell with the above expression vector.
  • the nucleic acid or expression vector may be integrated into the genome, or may exist as an autonomously replicable plasmid, but the nucleic acid is contained in a state capable of being transcribed.
  • Host cells may be prokaryotes, yeast, animal cells, insect cells, plant cells, etc., but preferably prokaryotes or yeast strains. Examples thereof include prokaryotes such as Escherichia coli and yeast strains such as Saccharomyces cerevisiae.
  • the recombinant cells of this embodiment can be used to produce conjugates that are the above polypeptides or fusion proteins.
  • a pharmaceutical composition of one embodiment is a pharmaceutical composition comprising a polypeptide of the above embodiments or a conjugate of the above embodiments.
  • the pharmaceutical composition may be a pharmaceutical composition for prevention, amelioration, or treatment of neurodegenerative diseases, and is particularly preferably a vaccine.
  • the dosage form of the pharmaceutical composition of the present embodiment may be, for example, liquid, powder (freeze-dried powder, dry powder), capsule, tablet, and frozen state.
  • the pharmaceutical composition of this embodiment may contain a pharmaceutically acceptable carrier.
  • the carrier may be one commonly used in vaccine manufacture, and specifically includes saline, buffered saline, dextrose, water, glycerol, isotonic aqueous buffers and combinations thereof.
  • Emulsifiers, preservatives (eg, thimerosal), tonicity agents, pH adjusters, inactivators (eg, formalin) and the like may be further added to the vaccine as appropriate.
  • Adjuvants include, for example, aluminum adjuvants or oil-in-water emulsion adjuvants containing squalene (AS03, MF59, etc.), CpG and Toll-like receptors such as 3-O-deacylated-4'-monophosphoryl lipid A (MPL). body ligands, saponin-based adjuvants, polymer-based adjuvants such as poly ⁇ -glutamic acid, polysaccharides such as chitosan and inulin, specifically aluminum hydroxide (Alum), CFA (Complete Freund's adjuvant) ( DIFCO) and the like.
  • Alum aluminum hydroxide
  • CFA Complete Freund's adjuvant
  • the pharmaceutical composition of the present embodiment can be produced by mixing the polypeptide or the conjugate as well as a carrier, adjuvant, and the like, if necessary.
  • An adjuvant may be mixed at the time of use.
  • the subject of administration of the pharmaceutical composition of this embodiment is mammals, particularly humans.
  • Administration routes of the pharmaceutical composition of the present embodiment include, for example, transdermal administration, sublingual administration, eye drop administration, intradermal administration, intramuscular administration, oral administration, enteral administration, nasal administration, intravenous administration, and subcutaneous administration. , intraperitoneal administration, or mouth-to-lung inhalation administration.
  • Methods of administering the pharmaceutical composition of the present embodiment include, for example, syringes, transdermal patches, microneedles, implantable sustained release devices, syringes with microneedles, needle-free devices, and methods of administration by spray.
  • the pharmaceutical composition of this embodiment is a pharmaceutical composition for the prevention, amelioration, or treatment of neurodegenerative diseases, where the neurodegenerative disease may be a disease associated with ⁇ -synuclein accumulation.
  • Accumulation of ⁇ -synuclein means accumulation of ⁇ -synuclein aggregates (also referred to as “aggregated ⁇ -synuclein” or “ ⁇ -synuclein oligomers”) in nerve cells, nerve fibers or glial cells.
  • Associated diseases include Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), neurodegeneration with brain iron accumulation (NBIA) and other synucleinopathies, particularly Parkinson's disease.
  • AD Alzheimer's disease
  • a ⁇ amyloid beta
  • myotrophic lateral sclerosis which is caused by the deposition of aggregates of the TDP-43 protein in the brain.
  • ALS is also considered a disease associated with accumulation of alpha-synuclein, as alpha-synuclein correlates with aggregation of these proteins.
  • the pharmaceutical composition of this embodiment contains an effective amount of the polypeptide or the conjugate, and is 0.0001 mg to 1000 mg, preferably 0.001 mg to 1000 mg, more preferably 0 mg in terms of the amount of the polypeptide. It preferably contains the polypeptide in an amount of .1 mg to 100 mg.
  • an anti-human ⁇ -synuclein antibody is induced in the subject, and the antibody specifically binds not only to human ⁇ -synuclein monomers but also to human ⁇ -synuclein oligomers.
  • neurodegenerative diseases caused by ⁇ -synuclein aggregates can be prevented, ameliorated, or treated.
  • the administration frequency and administration interval of the pharmaceutical composition of the present embodiment are not particularly limited, but it may be administered once or multiple times at intervals of several days to several months.
  • a single dose of the pharmaceutical composition of the present embodiment can be appropriately adjusted depending on the administration subject, administration method, etc., and is 0.0001 mg to 1000 mg, preferably 0.001 mg to 1000 mg, more preferably 0.1 mg to 100 mg. be.
  • the efficacy of the pharmaceutical composition of this embodiment can be evaluated by detecting anti-human ⁇ -synuclein antibodies in the serum of subjects to which it is administered.
  • a pharmaceutical composition of another embodiment is a pharmaceutical composition containing the nucleic acid or expression vector of the above embodiments.
  • the pharmaceutical composition of this embodiment may be a pharmaceutical composition for preventing, improving, or treating neurodegenerative diseases, and is particularly preferably a vaccine.
  • the nucleic acid or expression vector may be in the form of a liposome encapsulating the nucleic acid or expression vector, or a particulate carrier carrying the nucleic acid or expression vector.
  • the administration interval is as described in [Nucleic acid, expression vector, recombinant cell] above.
  • the dosage form of the pharmaceutical composition of this embodiment may be, for example, liquid, powder (freeze-dried powder, dry powder), capsule, tablet, or frozen state.
  • the pharmaceutical composition of this embodiment may contain a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of a further embodiment is a pharmaceutical composition containing the antibody of the above embodiments.
  • the pharmaceutical composition of this embodiment is a pharmaceutical composition for the prevention, amelioration, or treatment of neurodegenerative diseases, and the dosage, administration route, administration interval, etc. are as described in [Antibody] above.
  • the dosage form of the pharmaceutical composition of this embodiment may be, for example, liquid, powder (freeze-dried powder, dry powder), capsule, tablet, or frozen state.
  • the pharmaceutical composition of this embodiment may contain a pharmaceutically acceptable carrier.
  • One embodiment of the invention provides the use of the polypeptide of the above embodiments or the conjugate of the above embodiments in the manufacture of a vaccine for the prevention, amelioration or treatment of neurodegenerative diseases.
  • One embodiment of the invention provides an effective amount of a polypeptide of the above embodiments or a conjugate of the above embodiments to a subject in need thereof (e.g., a patient with a neurodegenerative disease or in need of prevention of a neurodegenerative disease).
  • a subject in need thereof e.g., a patient with a neurodegenerative disease or in need of prevention of a neurodegenerative disease.
  • a method for preventing, ameliorating, or treating a neurodegenerative disease is provided.
  • One embodiment of the present invention provides the nucleic acid of the above embodiment, the expression vector of the above embodiment, the recombinant cell of the above embodiment, or the production of a pharmaceutical composition for the prevention, amelioration, or treatment of a neurodegenerative disease.
  • Uses of the antibodies of the above embodiments are provided.
  • One embodiment of the present invention provides an effective amount of the nucleic acid of the above embodiments, the expression vector of the above embodiments, or the antibody of the above embodiments to a subject in need thereof (e.g., a patient with a neurodegenerative disease or a neurodegenerative disease). A subject in need of disease prevention).
  • One embodiment of the present invention provides the polypeptide of the above embodiments, the conjugate of the above embodiments, the nucleic acid of the above embodiments, the expression vector of the above embodiments, for use in preventing, ameliorating, or treating a neurodegenerative disease. , or an antibody of the above embodiments.
  • Example 1 Preparation of Various Epitope Peptides and Conjugates of Human ⁇ Syn
  • the ⁇ Syn epitope peptide (including the mimotope) and AJ peptide were synthesized.
  • the references “Solid Phase Peptide Synthesis, Pierce (1984)”, “Fmoc solid synthesis: a practical approach, Oxford University Press (2000)” and “5th Edition Experimental Chemistry Course 16 Synthesis of Organic Compounds IV, Japan Chemistry Society, 2005”, etc. a protected peptide resin was synthesized by the Fmoc method using a fully automatic solid-phase synthesizer.
  • Trifluoroacetic acid and a scavenger (mixture of thioaniol, ethanedithiol, phenol, triisopropylsilane, water, etc.) were added to the resulting protected peptide resin, and the peptide was cleaved from the resin and deprotected to obtain a crude peptide.
  • This crude peptide was purified using a reverse-phase HPLC column (ODS) with gradient elution in a 0.1% TFA-H20/CH3CN system. Fractions containing the desired product were collected and lyophilized to obtain the desired peptide.
  • the amino acid sequence of the synthesized peptide was confirmed using an amino acid sequencer G1000A (Hewlett Packard), PPSQ-23A (Shimadzu Corporation) or ProciscLC (ABI), and the N-terminus of the resulting peptide was acetylated.
  • p54 (96-104aa of SEQ ID NO: 14): KKDQLGKNE (SEQ ID NO: 1) p150 (123-131aa of SEQ ID NO: 14): EAYEMPSEE (SEQ ID NO: 2) p283 (123-132aa of SEQ ID NO: 14, E131D): EAYEMPSEDG (SEQ ID NO: 3) p142 (96-104aa of SEQ ID NO: 14, K102A): KKDQLGANE (SEQ ID NO: 4) p167 (96-105aa of SEQ ID NO: 14): KKDQLGKNEE (SEQ ID NO: 5) p227 (96-104aa of SEQ ID NO: 14, K97R): KRDQLGKNE (SEQ ID NO: 6) p233 (96-104aa of SEQ ID NO: 14, E104D): KKDQLGKND (SEQ ID NO: 7) p272 (96-104aa of SEQ ID
  • the AJ-human ⁇ Syn peptide conjugate is prepared by adding a protective group to the AJ peptide (SEQ ID NO: 13) and various epitope peptides of human ⁇ Syn synthesized above, and then connecting them via ⁇ -aminocaproic acid ( ⁇ -Acp) as a linker. , followed by condensation and deprotection to generate the various AJ-human ⁇ Syn peptide conjugates shown in Table 1.
  • the human ⁇ Syn peptide or AJ-human ⁇ Syn peptide conjugate is covalently bonded to the cysteine linker and the lysine residue present on the surface of the KLH protein. Ligation to generate KLH-human ⁇ Syn peptide conjugates or KLH-modified AJ-human ⁇ Syn peptide conjugates.
  • Example 2 Examination of Ability of AJ Peptide-Human ⁇ Syn Peptide Conjugate to Induce Antibodies against Human ⁇ Syn and Aggregated Human ⁇ Syn (1)
  • Various AJ peptide-human ⁇ Syn peptide conjugates prepared in Example 1 were used to evaluate their ability to induce antibodies against human ⁇ Syn in mice.
  • the ELISA was performed by the following method. 96-well plates were coated with human ⁇ Syn (Sigma) at 0.2 ⁇ g/well. After washing once with PBST (Phosphate Buffered Saline containing 0.05% Tween), blocking was performed with 3% skimmed milk (wako). After washing with PBST three times, diluted serum was added and allowed to react at room temperature for 1 hour. Furthermore, after washing with PBST three times, Goat anti-mouse IgG-HRP (abcam) was added and allowed to react at room temperature for 1 hour. After washing three times with PBST, SureBlue TMB Microwell Peroxidase Substrate (KPL) was added and allowed to react for 10 minutes at room temperature while shielding from light.
  • PBST Phosphate Buffered Saline containing 0.05% Tween
  • TMB Stop Solution KPL
  • absorbance at 450 nm was measured.
  • ELISA against aggregated human ⁇ Syn was performed by coating 15 ng/well of aggregated human ⁇ Syn (Stress Marq) instead of human ⁇ Syn in the above method.
  • Table 2 shows the results. Table 2 confirmed that administration of various AJ-human ⁇ Syn peptide conjugates induced antibodies against human ⁇ Syn in mouse sera. In addition, KLH-DMPVDPDN described in Patent Document 2 was also confirmed to induce antibodies against human ⁇ Syn. In addition, against aggregated human ⁇ Syn, although AJ-p167, AJ-p227, AJ-p272 and AJ-p283 were confirmed to have particularly strong antibody-inducing ability, the antibody-inducing ability of KLH-DMPVDPDN was very weak. .
  • Example 3 Examination of antibody-inducing ability of AJ-human ⁇ Syn peptide conjugate and KLH-modified AJ-human ⁇ Syn peptide conjugate KLH-human ⁇ Syn peptide conjugate (KLH-p54 and p54-KLH) prepared in Example 1 Furthermore, using KLH-AJ-human ⁇ Syn peptide conjugates (AJ-p54-KLH, KLH-AJ-p54), the ability of these conjugates to induce antibodies against human ⁇ Syn in mice was evaluated in the same manner as in Example 2. did. AJ-p54 was used as a comparison.
  • Table 3 shows the results. From Table 3, when using either AJ-human ⁇ Syn peptide conjugate (AJ-p54) or KLH-modified AJ-human ⁇ Syn peptide conjugate (AJ-p54-KLH, KLH-AJ-p54), It was confirmed that antibodies against human ⁇ Syn were induced to the same extent. For the KLH-modified AJ-human ⁇ Syn peptide conjugate, no difference in antibody titers was observed whether KLH was linked to the N-terminus or the C-terminus.
  • Example 4 Examination of ability of AJ-human ⁇ Syn peptide conjugate to induce antibodies against human ⁇ Syn and aggregated human ⁇ Syn (2) The ability of the AJ-human ⁇ Syn peptide conjugates (AJ-p54, AJ-p54-KLH, AJ-DMPVDPDN) prepared in Example 1 to induce antibodies against human ⁇ Syn and aggregated human ⁇ Syn in mice was evaluated.
  • Physiological saline, AJ-human ⁇ Syn peptide conjugate (250 ⁇ g/mouse), and Alum (InvivoGen, 50 ⁇ g/mouse) as an adjuvant were administered to balb/c mice (female, 6 weeks old, CLEA Japan) twice at 2-week intervals. was administered intramuscularly.
  • KLH-DMPVDPDN 25 ⁇ g/mouse was administered with Alum (InvivoGen, 50 ⁇ g/mouse) as an adjuvant.
  • ELISA was performed by the method described in Example 2.
  • Table 4 shows the results. Table 4 confirmed that AJ-p54 and AJ-p54-KLH induced antibodies against human ⁇ Syn and aggregated human ⁇ Syn in mice. However, although KLH-DMPVDPDN induced antibodies against human ⁇ Syn, it did not induce antibodies against aggregated human ⁇ Syn. In addition, AJ-DMPVDPDN showed a very weak antibody-inducing effect on both human ⁇ Syn and aggregated human ⁇ Syn.
  • Example 5 Examination of human ⁇ Syn-neutralizing action of antibody induced in mice by AJ-human ⁇ Syn peptide conjugate Antibodies induced in mice by the AJ-human ⁇ Syn peptide conjugate (AJ-p54) prepared in Example 1 was evaluated for the neutralizing effect of aggregated human ⁇ Syn.
  • Physiological saline, AJ-human ⁇ Syn peptide conjugate (250 ⁇ g/animal), and CFA (DIFCO) as an adjuvant were intramuscularly administered to C57BL/6 mice (male, 6 weeks old, CLEA Japan) 4 times at 2-week intervals. did.
  • KLH-DMPVDPDN (25 ⁇ g/mouse) was administered with Alum (InvivoGen, 50 ⁇ g/mouse) as an adjuvant. Serum was collected two weeks after the fourth dose. After collecting the antibodies contained in the serum by Protein G HP SpinTrap (Cytiva), the neutralizing action of human ⁇ Syn and aggregated human ⁇ Syn was evaluated by the method described below.
  • SH-SY5Y cells As a neutralizing effect of human ⁇ Syn or aggregated human ⁇ Syn, the effect on phosphorylation of human ⁇ Syn in SH-SY5Y cells (ATCC) was evaluated. SH-SY5Y cells were seeded in a 96-well plate at 2 ⁇ 10 4 cells/well and cultured at 37° C. and 5% CO 2 . The next day, human ⁇ Syn (wako) or aggregated human ⁇ Syn (Stress Marq) at different concentrations (5, 10, 20, 25 ⁇ g/mL) was added, and cultured for 3 more days.
  • phosphorylated human ⁇ Syn was stained with a fluorescently labeled anti-phosphorylated ⁇ Syn antibody (Cell Signaling). The amount of phosphorylated human ⁇ Syn was evaluated by image analysis using Array Scan (Thermo).
  • Example 6 Human ⁇ Syn Propagation Suppressive Effect in Human ⁇ Syn Overexpressing Mice
  • Antibodies induced by AJ-human ⁇ Syn peptide conjugates (AJ-p54, AJ-p150) reduced the amount of human ⁇ Syn in the brain of Parkinson's disease model mice.
  • KLH-DMPVDPDN (25 ⁇ g/mouse) was administered with Alum (InvivoGen, 50 ⁇ g/mouse) as an adjuvant.
  • Human ⁇ Syn-overexpressing mice were prepared according to the method described in Non-Patent Document 4 and used. Cortices and olfactory bulbs were harvested two weeks after the fourth administration. The amount of human ⁇ Syn in the soluble fraction in cortex and olfactory bulb was assessed by dot blot.
  • Sample preparation and dot blotting were performed by the following method.
  • the mouse cortex and olfactory bulb were each placed in a ceramic bead kit tube CK14 (MS equipment), ice-cold 1% Triton X-100, 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, Protease and Phosphatase Inhibitor Cocktail (Thermo ) was added. It was homogenized with Micro Smash MS-100R (TOMY) for 30 seconds at 5,500 rpm. Further, it was sonicated with a BIORUPTOR (BM Instruments).
  • TOMY Micro Smash MS-100R
  • BIORUPTOR BIORUPTOR
  • a membrane was set in a Dot Blot apparatus (Bio-Dot, Bio-Rad), 0.5 ⁇ g/well of soluble fractions of cortex and olfactory bulb was added, allowed to stand at room temperature for 1 hour, and then subjected to suction filtration. Blocking One (Nacalai Tesque) was added, allowed to stand at room temperature for 1 hour, and then blocked by suction filtration. After washing with PBS, Anti-Alpha-synuclein filament antibody (abcam, clone MJFR-14-6-4-2) was added, allowed to stand at room temperature for 2 hours, and then suction filtered.
  • FIG. 2A cortex
  • FIG. 2B olfactory bulb
  • FIGS. 2A and 2B Welch's t-test, ###: p ⁇ 0.005 against WT; Dunnett's test , *: p ⁇ 0.05 vs. vehicle, **: p ⁇ 0.01 vs. vehicle, ***: p ⁇ 0.005 vs. vehicle; vehicle: no antigen).
  • Administration of AJ-p150 significantly decreased the amount of human ⁇ Syn in the cortex.
  • administration of AJ-p54, AJ-p150 and KLH-DMPVDPDN significantly decreased the amount of human ⁇ Syn in the olfactory bulb. From the above results, it was revealed that the AJ-human ⁇ Syn peptide conjugate exhibits human ⁇ Syn propagation inhibitory action in human ⁇ Syn overexpressing mice.
  • the soluble fractions of the cortex and olfactory bulb were analyzed by Western blot. Specifically, 10 ⁇ g of soluble fractions of cortex and olfactory bulb were subjected to SDS-PAGE using 15-20% polyacrylamide gel (Fujifilm Wako Pure Chemical Industries) and Tris/Tricine/SDS buffer (Bio-Rad). The gel was placed on the membrane of Trans-Blot Turbo Mini 0.2 ⁇ m PVDF Transfer Packs (Bio-Rad), and proteins were transferred to the membrane using the blotting device Trans-Blot Turbo (Bio-Rad).
  • the membrane was transferred to a container containing 4% paraformaldehyde/phosphate buffer (Fujifilm Wako Pure Chemical Industries) and shaken at room temperature for 30 minutes. After washing the membrane three times by shaking it with PBS for 5 minutes, Blocking One (Nacalai Tesque) was added and the membrane was shaken at room temperature for 30 minutes for blocking. A 10,000-fold solution of the primary antibody alpha synuclein monoclonal antibody (clone: Syn211, Thermo) diluted 10-fold with PBST and diluted with Blocking One was added to the membrane and shaken overnight at 4°C.
  • paraformaldehyde/phosphate buffer Flujifilm Wako Pure Chemical Industries
  • FIG. 3A cortex
  • FIG. 3B olfactory bulb
  • FIGS. 3A and 3B Welch's t-test, ###: p ⁇ 0.005 against WT; Dunnett's test , *: p ⁇ 0.05 vs. Vehicle, ***: p ⁇ 0.005 vs. Vehicle; Vehicle: no antigen).
  • Administration of AJ-p150 significantly decreased the amount of human ⁇ Syn in the cortex.
  • administration of AJ-p54 and AJ-p150 significantly decreased the amount of human ⁇ Syn, but administration of KLH-DMPVDPDN did not significantly decrease the amount of human ⁇ Syn.
  • Example 7 Examination of ability of AJ-human ⁇ Syn peptide conjugate to induce antibodies against human ⁇ Syn and aggregated human ⁇ Syn in cynomolgus monkeys The ability of AJ-human ⁇ Syn peptide conjugates to induce antibodies against human ⁇ Syn and aggregated human ⁇ Syn in cynomolgus monkeys was evaluated.
  • AJ-human ⁇ Syn peptide conjugates (AJ-p54, AJ-p150, AJ-p283, AJ-p142, AJ-p273) 2000 ⁇ g/mouse) and KLH-DMPVDPDN (75 ⁇ g/mouse) were added to Alum (InvivoGen, 200 ⁇ g/mouse).
  • Alum InvivoGen, 200 ⁇ g/mouse.
  • cynomolgus monkeys male, 3-7 years old, Shin Nippon Kagaku
  • Example 8 Examination of human ⁇ Syn neutralizing effect of antibodies induced in cynomolgus monkeys Neutralizing effect of aggregated human ⁇ Syn by antibodies induced in cynomolgus monkeys by AJ-human ⁇ Syn peptide conjugates was evaluated. AJ-human ⁇ Syn peptide conjugates (AJ-p54, AJ-p150, 2000 ⁇ g/mouse) and KLH-DMPVDPDN (75 ⁇ g/mouse) were administered to cynomolgus monkeys (male, 3-7 years old) with Alum (InvivoGen, 200 ⁇ g/mouse) as an adjuvant.
  • AJ-human ⁇ Syn peptide conjugates AJ-p54, AJ-p150, 2000 ⁇ g/mouse
  • KLH-DMPVDPDN 75 ⁇ g/mouse
  • Example 9 Examination of Ability of AJ-Human ⁇ Syn Peptide Conjugate to Induce Antibodies against Human ⁇ Syn and Aggregated Human ⁇ Syn (3)
  • the following peptides were synthesized by the method described in Example 1, and then various human ⁇ Syn peptide conjugates shown in Table 5 below were produced by the method described in Example 1.
  • the various human ⁇ Syn peptide conjugates prepared were evaluated for their ability to induce antibodies against human ⁇ Syn and aggregated human ⁇ Syn in mice using the antibody titer against human ⁇ Syn and aggregated human ⁇ Syn of mouse immune sera by the method described in Example 2. evaluated.
  • Table 6 shows the results.
  • the antibody titer of AJ-p242, AJ-p244, AJ-p347, or AJ-p361 is shown with the antibody titer of AJ-p150 as a control being 1 (logarithm).
  • the antibody titers of AJ-p229, AJ-p237 and AJ-p298 were shown with the antibody titer of AJ-p54 as a control set to 1 (logarithm).
  • Example 10 Examination of Ability of AJ-Human ⁇ Syn Peptide Conjugates with Modified Linkers to Induce Antibodies against Human ⁇ Syn and Aggregated Human ⁇ Syn AJ-human ⁇ Syn peptide conjugates with modified linkers were made.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2022/024263 2021-06-18 2022-06-17 ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物 Ceased WO2022265091A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22825079.1A EP4357354A1 (en) 2021-06-18 2022-06-17 Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
US18/566,885 US20240270801A1 (en) 2021-06-18 2022-06-17 Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
JP2023530421A JPWO2022265091A1 (https=) 2021-06-18 2022-06-17

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021101745 2021-06-18
JP2021-101745 2021-06-18

Publications (1)

Publication Number Publication Date
WO2022265091A1 true WO2022265091A1 (ja) 2022-12-22

Family

ID=84527547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/024263 Ceased WO2022265091A1 (ja) 2021-06-18 2022-06-17 ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物

Country Status (5)

Country Link
US (1) US20240270801A1 (https=)
EP (1) EP4357354A1 (https=)
JP (1) JPWO2022265091A1 (https=)
TW (1) TW202306966A (https=)
WO (1) WO2022265091A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041067A2 (en) 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2009103105A2 (en) 2008-02-22 2009-08-27 Affiris Ag Mimotope
JP2013502379A (ja) * 2009-08-21 2013-01-24 アフィリス・アクチェンゲゼルシャフト アルファシヌクレイン・エピトープのミモトープのレヴィ小体病治療への使用
WO2017164409A1 (ja) 2016-03-25 2017-09-28 国立大学法人大阪大学 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
WO2018232369A1 (en) 2017-06-16 2018-12-20 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
WO2020212593A1 (en) * 2019-04-18 2020-10-22 Ac Immune Sa Novel molecules for therapy and diagnosis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041067A2 (en) 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2009103105A2 (en) 2008-02-22 2009-08-27 Affiris Ag Mimotope
JP2011512363A (ja) * 2008-02-22 2011-04-21 アフィリス・アクチェンゲゼルシャフト 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
JP2013502379A (ja) * 2009-08-21 2013-01-24 アフィリス・アクチェンゲゼルシャフト アルファシヌクレイン・エピトープのミモトープのレヴィ小体病治療への使用
WO2017164409A1 (ja) 2016-03-25 2017-09-28 国立大学法人大阪大学 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
WO2018232369A1 (en) 2017-06-16 2018-12-20 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のｃ末端からのペプチド免疫原及びその製剤
WO2020212593A1 (en) * 2019-04-18 2020-10-22 Ac Immune Sa Novel molecules for therapy and diagnosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Fmoc solid synthesis: a practical approach", 2000, OXFORD UNIVERSITY PRESS
"Jikken Kagaku Koza (Encyclopedia 16 of Experimental Chemistry", 2005, article "Synthesis IV of Organic Compounds"
GLENDA HALLIDAY ET AL.: "Milestones in Parkinson's Disease-Clinical and Pathologic Features", MOV. DISORD., vol. 26, 2011, pages 1051 - 1021
HODAKA YAMAKADO ET AL.: "a-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion", NEURO SCIENCE RESEARCH, vol. 73, 2012, pages 173 - 177, XP028419871, DOI: 10.1016/j.neures.2012.03.010
KATSUYA ARAKI ET AL.: "A small-angle X-ray scattering study of alpha-synuclein from human red blood cells", SCI REP., vol. 6, 2016, pages 30473
MARIA J MARTI ET AL.: "Clinical overview of the synucleinopathies", MOV DISORD., 2003, pages S21 - 7
PIERCE, SOLID PHASE PEPTIDE SYNTHESIS, 1984
R. B. MERRIFIELD ET AL., J. AM. CHEM. SOC., vol. 85, no. 14, 1963, pages 2149 - 2154

Also Published As

Publication number Publication date
JPWO2022265091A1 (https=) 2022-12-22
TW202306966A (zh) 2023-02-16
EP4357354A1 (en) 2024-04-24
US20240270801A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
US20230201320A1 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy
ES3040563T3 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR102638978B1 (ko) Rsv에 대한 백신
DK2467153T3 (en) USING MIMOTOPES OF ALFA SYNUCLEIN EPITOPES FOR THE TREATMENT OF LEWY BODY DISEASES
WO2020163646A1 (en) Anti-gitr antigen-binding domains and uses thereof
CN104520323B (zh) 用于治疗b细胞介导的炎性疾病的方法
KR20170003912A (ko) 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
US20230086093A1 (en) Mutant rsv f protein and use thereof
CA2791538A1 (en) Oligomer-specific amyloid beta epitope and antibodies
CN104066845A (zh) 可溶性IGF受体Fc融合蛋白和其用途
EP1711208A2 (en) Conjugates of amyloid proteins as vaccines for amyloid-related diseases
EP4594345A1 (en) Protease-activated polypeptides
WO2022207645A1 (en) Sars-cov-2 subunit vaccine
WO2023008553A1 (ja) 変異型コロナウイルスに対するニワトリ抗体
CN112898426A (zh) 人源化4-1bb单克隆抗体及其药物组合物
JP2025503079A (ja) キメラポリペプチド
WO2022265091A1 (ja) ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物
EP4203999A1 (en) Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
US11203644B2 (en) Anti-TLR9 antibody, pharmaceutical composition, and kit
US20240226279A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
US20240218056A1 (en) Nucleocapsid-specific antibodies and methods for the treatment and prevention of sars-cov-2 infection therewith
NZ713371A (en) Stabilized soluble prefusion rsv f polypeptides
HK1170658B (en) Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22825079

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023530421

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022825079

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022825079

Country of ref document: EP

Effective date: 20240116

WWW Wipo information: withdrawn in national office

Ref document number: 2022825079

Country of ref document: EP